Junevity
Junevity is a biotechnology company founded at UCSF in 2023, dedicated to extending human healthspan and lifespan through innovative Cell Reset therapeutics. They utilize a platform that combines large-scale human data, AI/ML, and siRNA technology to develop safe and effective therapeutics targeting transcription factors involved in aging and age-related diseases. Their mission is to reverse cellular damage and restore tissue health, aiming to treat diseases such as Type 2 Diabetes, Obesity, Osteoarthritis, and Sarcopenia, with the vision of a world with longer, healthier lives.
Industries
Nr. of Employees
small (1-50)
Junevity
Products
Preclinical siRNA program — Type 2 Diabetes
Preclinical development program for an siRNA therapeutic aimed at improving insulin sensitivity and metabolic function.
Preclinical siRNA program — Obesity
Preclinical development program for an siRNA therapeutic targeting pathways linked to obesity.
Preclinical siRNA program — Osteoarthritis
Preclinical development program for an siRNA therapeutic aimed at reversing transcriptional damage associated with osteoarthritis.
Preclinical siRNA program — Sarcopenia
Preclinical development program for an siRNA therapeutic addressing muscle degeneration associated with aging.
Preclinical siRNA program — Type 2 Diabetes
Preclinical development program for an siRNA therapeutic aimed at improving insulin sensitivity and metabolic function.
Preclinical siRNA program — Obesity
Preclinical development program for an siRNA therapeutic targeting pathways linked to obesity.
Preclinical siRNA program — Osteoarthritis
Preclinical development program for an siRNA therapeutic aimed at reversing transcriptional damage associated with osteoarthritis.
Preclinical siRNA program — Sarcopenia
Preclinical development program for an siRNA therapeutic addressing muscle degeneration associated with aging.
Services
Integrated discovery platform service
Collaborative discovery service that combines large-scale human data, laboratory validation, and AI/ML to identify transcription factor targets and develop siRNA strategies.
Partnering for siRNA therapeutic development
Collaborative programs with external companies to co-develop siRNA therapeutics targeting transcription factors implicated in aging-related diseases.
Integrated discovery platform service
Collaborative discovery service that combines large-scale human data, laboratory validation, and AI/ML to identify transcription factor targets and develop siRNA strategies.
Partnering for siRNA therapeutic development
Collaborative programs with external companies to co-develop siRNA therapeutics targeting transcription factors implicated in aging-related diseases.
Expertise Areas
- siRNA therapeutic development
- Transcriptomics and transcription factor discovery
- Bioinformatics and machine learning for target prioritization
- Preclinical discovery and candidate selection
Key Technologies
- siRNA therapeutics
- Human bulk transcriptomics
- Spatial transcriptomics
- Machine learning for biology